Potassium Iodide

A 130 mg tablet of potassium iodide delivers about 100 mg of iodide. The adult recommended intake of iodine is 150 micrograms per day and the tolerable upper intake level is 1,100 micrograms per day, so one tablet is roughly 660 times the daily requirement and about 90 times the upper limit. That is a pharmacologic dose of a hormone precursor, not a nutritional top-up, and the case for taking it rests entirely on a specific and rare exposure. There is no version of daily use that makes sense for a healthy person.

For a single dose in a healthy population the safety record is genuinely reassuring. The Polish mass prophylaxis after Chernobyl reached about 16 million people with a single administration and produced only rare side effects ^[10][9]. A systematic review of adverse effects of iodine thyroid blocking found no severe reactions in the general public, while noting frankly that the evidence base is weak because the intervention is so rarely used and most of what is known has to be borrowed from other settings ^[17]. Side effects in adults should not be overestimated; newborns and infants are the group with real reason for caution ^[8]. Guidance in several countries also advises against giving it to people over 60 and to adults with cardiovascular disease, where the balance tips the other way ^[12].

Repeated or chronic iodide excess is a different animal. Iodine-induced hypothyroidism happens when the thyroid fails to escape the Wolff-Chaikoff block, and the people at risk are exactly the people with an already abnormal gland: Hashimoto thyroiditis, prior radioiodine treatment, prior thyroid surgery, and the fetal or neonatal thyroid, which acquires the ability to escape only late in gestation ^[4][3]. The threshold is lower than most people assume. In a controlled study of euthyroid Hashimoto patients given just 250 micrograms of potassium iodide daily, seven of 40 developed subclinical hypothyroidism and one became overtly hypothyroid, against a single case in 43 controls, and one patient went the other way into hyperthyroidism ^[19]. That is a quarter of a milligram, not a hundred milligrams.

Iodine-induced hyperthyroidism, the Jod-Basedow phenomenon, is the mirror image. It occurs when a gland containing autonomous nodules, usually the legacy of long-standing iodine deficiency, is suddenly handed enough substrate to run at full output; those nodules carry somatic mutations that constitutively activate the TSH receptor and are no longer under pituitary control ^[4]. It has been documented in epidemic form during national iodisation programmes, most often in older people with long-standing nodular goitre, and it is also triggered by iodine-rich drugs and by radiocontrast ^[18]. Chronic high iodine intake appears in addition to promote classical thyroid autoimmunity, meaning hypothyroidism and thyroiditis, and iodine-induced hyperthyroidism may itself have an autoimmune component ^[4].

Iodism is the dose-dependent toxidrome of sustained iodide: metallic taste, burning mouth and throat, sore teeth and gums, coryza and sneezing, headache, gastrointestinal upset, and acneiform or bullous skin eruptions ^[23]. Painful salivary gland swelling, historically called iodide mumps, is the same phenomenon in another tissue that concentrates iodide. These belong to the sustained dermatologic and expectorant regimens rather than to a single emergency tablet, and they resolve when the drug stops.

Three groups should not take it at all. Documented iodide hypersensitivity, dermatitis herpetiformis and hypocomplementaemic vasculitis are the standing contraindications in the FDA labelling for emergency potassium iodide. The dermatitis herpetiformis contraindication is not theoretical: iodine provocation has been used diagnostically in that disease precisely because it reliably brings lesions out, positive in about 78 percent of a series of 80 untreated patients ^[21]. Caution rather than prohibition applies to multinodular goitre, Graves disease and autoimmune thyroiditis, particularly once dosing runs past a day or two. Where iodine genuinely cannot be given, potassium perchlorate is the recognised alternative for thyroid blocking ^[8].

One myth is worth killing on the page. A shellfish or seafood allergy does not predict a reaction to iodine or to iodinated agents. Iodine is not an allergen; it is an element that every human thyroid already contains. The rate of reaction in people with a seafood allergy is comparable to the rate in people with any other food allergy or with asthma, and severe reactions and deaths have not been linked to so-called iodine allergy or to shellfish allergy ^[22]. The allergens in shellfish are muscle proteins. Refusing potassium iodide during a radiation emergency on the strength of a prawn allergy would be a mistake.

Two practical points close this out. Anyone on lithium is already taking a drug that blocks thyroid hormone release, and lithium combined with iodine has documented synergism in producing hypothyroidism ^[20]. And because potassium iodide is a potassium salt, the labelling warns about combining it with potassium-sparing diuretics, ACE inhibitors or angiotensin receptor blockers. The size of that load deserves honesty: a 130 mg tablet carries only about 0.8 mmol of potassium, which is trivial next to a banana. The warning bites far harder for SSKI, where a single millilitre carries roughly 6 mmol and a full dermatologic course runs for weeks.

Lithium blocks thyroid hormone release on its own, and lithium combined with iodine has documented synergism in causing hypothyroidism, so the pair is an additive risk rather than a theoretical one ^[20]. Amiodarone is an iodine-rich drug that delivers an enormous chronic iodine load, and adding potassium iodide on top of it is adding iodine to someone already saturated; amiodarone-treated patients are among the most likely to have unstable thyroid function in either direction. Thionamides such as methimazole and propylthiouracil matter for sequence rather than avoidance: in thyroid storm and in preoperative preparation, iodide follows the thionamide so the extra substrate does not feed fresh hormone synthesis ^[26].

Because the tablet is a potassium salt, the labelling warns about potassium-sparing diuretics, ACE inhibitors and angiotensin receptor blockers; the load from a single 130 mg tablet is about 0.8 mmol and is not clinically meaningful, but SSKI carries roughly 6 mmol per millilitre and a sustained dermatologic course is a different proposition. Other iodine sources stack: iodinated radiocontrast, povidone-iodine applied to large wounds, iodine-containing expectorants, kelp and sea moss supplements, and iodised salt all feed the same pool, and each has been implicated in iodine-induced thyroid disease ^[18]. Anyone on levothyroxine or an antithyroid drug should expect a large iodide dose to move their thyroid function tests.

Checking a whole stack? Run it through interactions + stacks.

Iodine was discovered by accident in 1811, when Bernard Courtois added too much sulfuric acid to seaweed ash while making saltpetre and got a violet vapour. Medicine reached for it almost immediately. In 1820 the Geneva physician Jean-Francois Coindet gave iodine tincture to patients with goitre and watched the goitres soften and shrink. Elemental iodine is barely soluble in water, and in 1829 Jean Guillaume Auguste Lugol solved that by dissolving iodine together with potassium iodide, producing the aqueous solution of 5 percent iodine and 10 percent potassium iodide that still carries his name and still appears in pharmacopoeias. Lugol's own interest was scrofula, the tuberculous lymphadenitis of the period, and he read his first memoir on iodine in scrofulous disease to the Paris Academy of Sciences that year. Through the nineteenth century potassium iodide became one of the standard remedies of the era, given alongside mercury for tertiary syphilis, sold as an expectorant, and from the early twentieth century used for sporotrichosis, which is the one of those indications that survives.

The modern story starts on 26 April 1986. Chernobyl released radioiodine over Belarus, Ukraine, the Russian Federation and much of Europe, and produced the clearest natural experiment the field has. Poland, downwind and iodine-deficient, decided within days to run a mass prophylaxis programme; roughly 16 million people received a single administration of stable iodide, side effects were rare, and the projected thyroid radiation dose was probably cut by around 40 percent ^[10][9]. The affected Soviet republics did not do this at scale or in time. What followed there was a more than tenfold rise in childhood thyroid cancer, concentrated in those exposed youngest. A population-based case-control study in Belarus and the Russian Federation later found a strong dose-response relationship, an odds ratio of thyroid cancer at 1 Gy of between 5.5 and 8.4, a risk three times higher in iodine-deficient areas, and a threefold reduction in radiation-related thyroid cancer risk among those who had taken potassium iodide as a dietary supplement ^[11]. The divergence between Poland and its neighbours is the strongest single piece of evidence that the intervention works, and it also shows what the intervention is worth: a partial reduction in a dose, not immunity.

Chernobyl changed policy as well. The United States had no public distribution of potassium iodide at all through the 1990s; the argument from federal agencies was that stockpiling and distribution to anyone other than emergency workers could not be justified on distribution logistics and cost-effectiveness grounds, even while the World Health Organization was urging general availability and other countries were already stockpiling ^[10]. That position broke in 2001, when the Nuclear Regulatory Commission amended its emergency planning rules to require that potassium iodide be considered as a protective measure for the general public alongside sheltering and evacuation, and FDA issued its age-stratified dosing guidance the same year. The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 went further and directed that tablets be made available for the population within 20 miles of a nuclear power plant, though that provision was waived in 2008 and never fully implemented. Federal and state stockpiles exist, public uptake is low, and because the salt is chemically stable FDA runs a formal shelf-life extension programme for government stockpiles rather than replacing them on a schedule.

Fukushima in March 2011 tested a different failure mode. The release was prolonged rather than a single puff, which exposed the fact that guidance had been written around one dose and had little to say about repeated dosing ^[8]. The French PRIODAC programme was set up to answer exactly that question and eventually produced a repeated-dosing authorisation ^[14]. The 2022 invasion of Ukraine wrote the next chapter, a continent-wide run on potassium iodide driven by fear of nuclear weapons rather than by any release, along with a matching crop of guidance about what the drug does and does not do, and a reminder that household iodine preparations are not a substitute for the pharmaceutical form ^[15].